Feasibility of ultra high field 7.0 Tesla MR Spectroscopy for monitoring neo-adjuvant therapy efficacy.

Feasibility of ultra high field 7.0 Tesla MR Spectroscopy for monitoring neo-adjuvant therapy efficacy. - Monitoring neo-adjuvant therapy in breast cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38209

Enrollment

Registered

2011-06-06

Start date

2012-02-27

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer breast neoplasm

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years or older - Females - breast cancer patients selected for neo-adjuvant therapy

Exclusion criteria

Exclusion criteria: - Any prior surgery or radiotherapy to the ipsilateral breast - Karnofsky score

Design outcomes

Primary

Measure	Time frame
1. What change in phospholipid metabolites can be detected with 7T MRS during neo-adjuvant therapy in breast cancer? 2. How strong does the change in phospholipid metabolism correlate to the efficacy of therapy as obtained from histology and with tumor volume as measured with standard contrast enhanced MRI.	—

Secondary

Measure	Time frame
How accurate can phospho-esters be determined with in vivo 7T MRS compared to ex vivo analysis with LC-MS en HR MAS MRS?	—

Countries

Netherlands

Outcome results